ID
33744
Description
Study ID: 102936 Clinical Study ID: HZA102936 Study Title:A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01209026 https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma The study consists of a screening, 4 treatment periods and a follow up. Treatment periods 1-4 are each 7 days long. Treatment period 1 Days 1-6 (TP1D-D6) Treatment period 1 Day 7 (TP1D7) Treatment period 2 Days 1-6 (TP2D1-D6) Treatment period 2 Day 7 (TP2D7) Treatment period 3 Days 1-6 (TP3D1-D6) Treatment period 3 Day 7 (TP3D7) Treatment period 4 Days 1-6 (TP4D1-D6) Treatment period 4 Day 7 (TP4D7) This document contains the PGx-Pharmacogenetic research consent (PGx Consent) form. It has to be filled in for the end of study. This form should only exist once in the study and is conditional upon inclusion of Pharmacogenetics in the protocol.
Link
https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026
Keywords
Versions (1)
- 12/21/18 12/21/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
December 21, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Effect of inhaled fluticasone furoate/Vilanterol combination on electrocardiographic parameters in healthy subjects, NCT01209026
PGx-Pharmacogenetic research consent (PGx Consent)
- StudyEvent: ODM
Description
PGx-Pharmacogenetic research consent
Alias
- UMLS CUI-1
- C0021430
- UMLS CUI-2
- C2347500
Description
Informed consent for PGx-Pharmacogenetic research
Data type
text
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C2347500
Description
day month year
Data type
date
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C0011008
Description
Blood sample collection for PGx-pharmacogenetic (DNA) research
Data type
text
Alias
- UMLS CUI [1,1]
- C0005834
- UMLS CUI [1,2]
- C2347500
Description
day month year
Data type
date
Alias
- UMLS CUI [1]
- C1302413
Description
Reason for no informed consent for PGx-Pharmacogenetic research
Data type
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C1298908
- UMLS CUI [1,3]
- C0021430
- UMLS CUI [1,4]
- C2347500
Description
Other Reason for no informed consent for PGx-Pharmacogenetic research
Data type
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C1298908
- UMLS CUI [1,3]
- C0021430
- UMLS CUI [1,4]
- C2347500
- UMLS CUI [2]
- C0205394
Similar models
PGx-Pharmacogenetic research consent (PGx Consent)
- StudyEvent: ODM
C2347500 (UMLS CUI-2)
C2347500 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C2347500 (UMLS CUI [1,2])
C1298908 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C2347500 (UMLS CUI [1,4])
C1298908 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C2347500 (UMLS CUI [1,4])
C0205394 (UMLS CUI [2])
No comments